Advanced Pacemaker for Treating Chronotropic Incompetence

Pacemakers are designed to treat bradycardia, a condition in which the heart beats too slowly, usually less than 60 beats per minute, depriving the body of sufficient oxygen. The INGENIO and ADVANTIO pacemakers from Boston Scientific feature RightRate pacing technology designed to treat chronotropic incompetence—the inability of the heart to regulate its rate appropriately in response to physical activity, which may cause patients to feel tired or short of breath during daily activities such as walking or climbing stairs. RightRate employs Boston Scientific’s minute ventilation sensor, the only sensor clinically proven to restore chronotropic competence, and adds programming options to promote ease of use and in-clinic time savings. In addition to RightRate, the INGENIO pacemaker offers Respiratory Rate Trend, an exclusive feature that monitors respiration—a key vital sign. The INVIVE cardiac resynchronization therapy pacemaker offers Respiratory Rate Trend as part of HF Perspectiv—a comprehensive suite of heart failure diagnostics designed to provide healthcare professionals with additional information to guide treatment decisions.

The INGENIO, ADVANTIO, and INVIVE devices are designed for use with Boston Scientific’s new LATITUDE NXT Remote Patient Management system, which is currently under review by the FDA, and will enable physicians to conduct remote follow-ups of these device patients to monitor specific pacemaker information and heart health status. The system is designed to detect clinical events between scheduled visits and send relevant data directly to a secure physician-accessible Web site via landline or cellular technology (under an agreement between Boston Scientific and AT&T wireless network).

Boston Scientific announces the U.S. FDA approval and U.S. market launch of INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers. The first implant of the INGENIO pacemaker in the United States was performed on May 3, 2012 by Bruce L. Wilkoff, M.D., Director of Cardiac Pacing and Tachyarrhythmia Devices at the Cleveland Clinic. Last month, Boston Scientific announced the CE Mark approval and European market launch of all three products.